FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC
Bevacizumab Biosimilar Equally Effective in Metastatic Colorectal Cancer
Treatment Combinations Based in Immune Checkpoint Inhibitors Provide Survival Benefits in CRC
Mass-Mailed Stool Tests Helped Improve Odds of Adherence, CRC Test Return
A Look at Cancers Where Biomarkers Are Needed
Dr Ajay Goel Explains Effectiveness of Liquid Biopsies, Tissue-Based Biomarkers in Treating CRC
Dr Ajay Goel Discusses New Methods of Testing for EOCRC, Recurrence
Botensilimab and Balstilimab in Refractory Microsatellite Stable (MSS) mCRC
Impact of Microsatellite Stability in Metastatic Colorectal Cancer
Utilizing RWE to Address Unmet Needs for CRC
ASCO GI 2023: SUNLIGHT Study
Neoadjuvant Immunotherapy Promising in CRC, but Long-term Data Needed, Says Dr Kristen Ciombor
Dr Kristen Ciombor: Neoadjuvant Immunotherapy in CRC Reduces Need for Other Treatments
Dr Kristen Ciombor on Precision Medicine Approaches in Colorectal Cancer
OS Disparity, Driver Gene Variations by Race and Ethnicity Seen in CRC
Updated Colonoscopy Guidelines Have Implications on Doctors, Patients Alike